Latest Office News

Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.

Altamin has completed the technical work underpinning its Lazio Scoping Study, but pushed the release to the end of Q1 2027 while reporting A$1.56 million in cash and a 1.41-quarter funding estimate. The company has drawn A$1 million from a shareholder-linked facility and is relying on further debt, grant reimbursements, a possible Gorno transaction and potential equity funding to support its plans.

Lindian Resources says its Kangankunde rare earths project remains on track for first monazite concentrate production in December, with equipment testing and export preparations now underway. The company also reported $45 million in cash, full ownership of its Kazakhstan processing plant and a newly disclosed appeal of a previously dismissed Malawi court case.

Valiant Gold has moved its Comet mine restart from re-entry into a construction and commissioning phase, with power, ventilation and dewatering systems advancing ahead of a H2 FY27 production target. The company ended the September quarter with $62.5 million in cash and term deposits while drilling at Reedy continued to test resource growth.

Pure Foods Tasmania reported a sharper September quarter, with customer receipts rising to A$1.22 million while operating cash outflow fell to A$311,000. The company remains cash flow negative and reliant on financing capacity, but says the figures mark progress towards a sustainable turnaround.

Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.

Biome Australia has reported record pharmacy sell-through, further market-share gains and positive operating cash flow as it begins manufacturing Activated Probiotics domestically. The quarter also moved its China expansion and BMB18 clinical trial closer to key execution milestones.

oOh!media’s proposed $1.68-per-share takeover by I Squared Capital has cleared the New Zealand Overseas Investment Office, removing one condition to the scheme. FIRB approval, shareholder approval and court sanction remain outstanding before the transaction can proceed.

Sports Entertainment Group delivered sharp FY26 operating growth, with revenue up 39% and underlying EBITDA up 73% to A$18.2 million. The result arrives as SEG takes on MediaWorks New Zealand, suspends its final dividend and shifts from a largely Australian sports media business towards a larger trans-Tasman platform.

Saluda Medical delivered 28% FY26 revenue growth and expanded its spinal cord stimulation opportunity with CAP24, but its annual report warns that additional capital may be needed within 12 months. The ASX-listed medical device company also begins FY27 under new CEO Michael Mathias.

Lithium Universe’s CEO and chief technical officer will leave on 30 October, prompting a search for a new chief executive while the company advances its lithium refining and recycling plans. No interim CEO or successor has been announced.

EVT delivered a 17% lift in normalised first-quarter EBITDA to $72.5 million, powered by a sharp recovery in Entertainment and resilient Hotels trading. Thredbo was the drag, while an $800 million property sell-down and ongoing structure review put the group’s Hotels-led strategy under the spotlight.